Momenta Pharmaceuticals

Momenta Pharmaceuticals. It was a biotechnology company founded in 2001 and headquartered in Cambridge, Massachusetts, focused on the detailed structural analysis and engineering of complex drugs. The company specialized in the development of generic versions of complex biologic medicines, known as biosimilars, as well as novel therapeutics for rare immune-mediated diseases. Its scientific foundation was built upon pioneering research from the Massachusetts Institute of Technology.

History

The company was co-founded in 2001 by professors Ram Sasisekharan and Ganesh Venkataraman Kaundinya, based on their research at the Massachusetts Institute of Technology and the Harvard-MIT Division of Health Sciences and Technology. It completed an initial public offering on the NASDAQ in 2004, raising significant capital to advance its platform. A major early milestone was the 2010 Food and Drug Administration approval of its first product, a generic version of Lovenox, which was developed in collaboration with Novartis's Sandoz division. Throughout the subsequent decade, the company expanded its focus from generic complex drugs to include a robust pipeline of novel biologic therapeutics targeting autoimmune diseases.

Business and operations

The company operated with a dual-strategy business model, encompassing both the analysis and development of follow-on biologics and the creation of novel drug candidates. Its core technology platform was centered on advanced analytical techniques for characterizing the structure and function of complex sugars attached to proteins, which are critical for many biologic drugs. Primary research and development activities were conducted at its facilities in Cambridge, Massachusetts, leveraging the dense biotech ecosystem of the Boston area. Leadership under former CEO Craig A. Wheeler steered the company through significant regulatory and commercial challenges in the biosimilar arena.

Products and pipeline

Its first commercial product was a generic version of the anticoagulant enoxaparin (Lovenox), which gained approval from the Food and Drug Administration in 2010. The company also developed a biosimilar of Copaxone (glatiramer acetate), a therapy for multiple sclerosis, marketed by its partner Sandoz. In the novel therapeutics arena, its pipeline included nipocalimab, an anti-FcRn antibody being investigated for conditions like warm autoimmune hemolytic anemia and myasthenia gravis. Another key investigational asset was M254, a hyper-sialylated IVIg candidate designed for treating immune thrombocytopenia and other autoimmune disorders.

Collaborations and partnerships

A foundational and long-standing partnership was with Sandoz, the generics division of Novartis, for the development and commercialization of several biosimilars, including the generic Lovenox and the Copaxone generic. The company also entered into a strategic collaboration with Mylan (now part of Viatris) focused on developing and marketing a portfolio of biosimilars in various global markets. Additional research collaborations included work with the CARB-X initiative to combat antibiotic resistance. It also licensed technology from Hanwha Chemical and engaged in partnerships with several smaller biotech firms to advance its novel drug platforms.

Acquisition by Johnson & Johnson

In October 2020, Johnson & Johnson announced a definitive agreement to acquire the company for approximately $6.5 billion. The acquisition was executed through Johnson & Johnson's pharmaceutical subsidiary, Janssen Pharmaceuticals. The primary strategic driver for Johnson & Johnson was to gain full rights to nipocalimab, a key late-stage asset in its Janssen Pharmaceuticals pipeline for autoimmune diseases. Following the completion of the acquisition in 2020, its operations and research programs were integrated into the Janssen Pharmaceuticals organization, ceasing its existence as an independent entity.

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Pharmaceutical companies established in 2001